Please use this identifier to cite or link to this item: http://repo.lib.jfn.ac.lk/ujrr/handle/123456789/7607
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRajasooriyar, C.
dc.contributor.authorMoorthy, T.
dc.contributor.authorRanatunge, N.
dc.contributor.authorGinige, A.
dc.contributor.authorSurenthirakumaran, R.
dc.date.accessioned2022-09-26T05:46:35Z-
dc.date.available2022-09-26T05:46:35Z-
dc.date.issued2020
dc.identifier.citationProceedings JMA-September - 2020en_US
dc.identifier.urihttp://repo.lib.jfn.ac.lk/ujrr/handle/123456789/7607-
dc.language.isoenen_US
dc.publisherJaffna Medical Associationen_US
dc.subjectEsophageal canceren_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectMutationen_US
dc.titleSignificant incidence of braf p.V600E mutations in esophageal cancer sets the stage for potential use of tyrosine kinase inhibitorsen_US
dc.typeResearch abstracten_US
Appears in Collections:Community & Family Medicine

Files in This Item:
File Description SizeFormat 
OP14.pdf459.2 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.